GELS Gunggung Aset Perusahaan Gelteq Limited

Simbol resmi perusahaan Gelteq Limited (GELS)

Gelteq Limited (GELS) generates revenue by licensing innovative gel-based medication delivery systems to pharmaceutical manufacturers. However, substantial technology certification costs and the risk of insurance reimbursement denials exert pressure on capital. This chart confirms that the market price reflects total assets of 14.48, supporting the B2B company's operations in developing injection alternatives for individuals with swallowing disorders.

gelteq.com - Total Aset Perusahaan GELS (periode 30.10.2024 - 29.10.2026)

Rincian metrik keuangan lan pasar gelteq.com (GELS)

- kuotasi saiki lan rata-rata prakiraan nilai:
Bagan bursa Gelteq|GELS - Bagan rega target
- data kapitalisasi pasar:
Kapitalisasi pasar GELS|GELS - Nilai Total Perusahaan
- data nilai buku modal saham:
Nilai Buku Saham Gelteq|GELS - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku gelteq.com|GELS - Total Aset Perusahaan
- rincian utang lan likuiditas:
Rasio Total Utang marang Ekuitas Gelteq Limited|GELS - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal Gelteq|GELS - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku GELS|GELS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Gelteq|Koefisien jangkoan perantara gelteq.com
- rincian asil keuangan lan kelipatan valuasi:
GELS - Penghasilan resik
Pambiji fundamental:Gelteq Limited
Barang utama Gelteq Limited Inc

The scaling of the Gelteq Limited (GELS) gel drug ecosystem and its expansion into the veterinary sector directly determine the volume of resources required to maintain patent protection and achieve FDA certification. The trend of this metric, calculated inversely via ROA, reflects the total value of assets; by analyzing fluctuations in assets and resources, investors must distinguish organic growth from the hidden accumulation of illiquid liabilities.

Pesaing utama

VRTX - Gunggung Aset Perusahaan|Aset Agregat Perusahaan Alnylam|Insmed Inc. (INSM) - Gunggung Aset Perusahaan|Aset Agregat Perusahaan United Therapeutics Corp. (UTHR)|BMRN: Nilai Total Aset Perusahaan|Total Aset Perusahaan BBIO (BridgeBio Pharma, Inc.)|BGM Group Limited (BGM) - Aset Perusahaan|Cogent Biosciences, Inc. - Total Aset Perusahaan|Xeris Biopharma Holdings, Inc. (XERS) - Gunggung Aset Perusahaan|KROS: Total Aset Perusahaan|ARCT - Gunggung Aset Perusahaan|ETON (Eton Pharmaceuticals) - Total Aset Perusahaan|Total Aset Perusahaan kamada.com|Aset Agregat Perusahaan Fulcrum Therapeutics, Inc. (FULC)|Aset Agregat Perusahaan ABEO (abeonatherapeutics.com)|Total Aset Perusahaan MREO (Mereo BioPharma Group plc)|Gunggung Aset Perusahaan Protalix BioTherapeutics, Inc (PLX)|PLRX: Gunggung Aset Perusahaan|Nilai Total Aset Perusahaan APLT|RNTX: Total Aset Perusahaan|Aset Perusahaan Aytu BioPharma (AYTU)|CMMB (Chemomab Therapeutics Ltd) - Total Aset Perusahaan|Total Aset Bisnis SRXH (SRx Health)|Gunggung Aset Perusahaan PLRZ (Polyrizon Ltd)|AEZS (zentaris.com) - Nilai Agregat Aset|Aset Agregat Perusahaan Cyclo Therapeutics, Inc. CYTH|INZY (Inozyme Pharma Inc.) - Nilai Total Aset Perusahaan|Reneo Pharma - Total Aset Perusahaan|Nilai Agregat Aset CSCI (COSCIENS Bio)